Skip to main content
PERCHERON THERAPEUTICS LIMITED logo

PERCHERON THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PER ISIN · AU0000317281 LEI · 984500FF63A961E0K787 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,206 across all filing types
Latest filing 2025-03-05 Regulatory Filings
Country AU Australia
Listing ASX PER

About PERCHERON THERAPEUTICS LIMITED

https://percherontx.com

Percheron Therapeutics Limited is a clinical-stage company focused on the development of novel antisense pharmaceuticals for rare diseases. The company's lead program, ATL1102, is an antisense oligonucleotide targeting the CD49d receptor, a subunit of the VLA-4 integrin. This therapeutic candidate is primarily being developed for the treatment of Duchenne muscular dystrophy (DMD), where it aims to reduce inflammation and muscle damage by modulating the immune system's response. Formerly known as Antisense Therapeutics, the firm utilizes its proprietary antisense technology platform to create targeted therapies that inhibit the production of proteins associated with disease progression. The company's research and development efforts are centered on addressing significant unmet medical needs through precision genetic medicine.

Recent filings

Filing Released Lang Actions
Response to ASX Query 8 pages 383.3KB
Regulatory Filings Classification · 95% confidence The document is a detailed response letter from Percheron Therapeutics Limited to the Australian Securities Exchange (ASX) regarding a query about a director's trading activity during a closed period. It discusses compliance with ASX Listing Rules, the company's securities trading policy, and the circumstances around the director's share transactions. The content focuses on regulatory compliance, disclosure obligations, and internal governance related to director dealings in company securities. It is not a financial report, earnings release, or management discussion, but rather a regulatory compliance communication addressing a specific issue raised by the exchange. This fits the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2025-03-05 English
Results of General Meeting 2 pages 165.7KB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an ASX announcement dated 4 March 2025 reporting the results of a General Meeting of shareholders. It includes detailed poll voting results on resolutions considered at the meeting, such as removal and election of directors. The text references compliance with Listing Rule 3.13.2 and section 251AA(1) of the Corporations Act, which govern disclosure of meeting results. The document is concise (3724 characters) and focuses solely on the voting outcomes rather than the meeting materials or the meeting itself. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA), which covers official results from shareholder votes at any general meeting. It is not a full Annual Report, Management Report, or Proxy Solicitation. Therefore, the correct classification is DVA with high confidence.
2025-03-03 English
Change of Director's Interest Notice - Dr James Garner 2 pages 222.7KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details the change in securities holdings of a company director, including the number of shares held before and after the change, the nature of the change, and dates. This is a clear report of personal share transactions by a company director, which fits the definition of 'Director's Dealing'. The document length is 3786 characters, which is consistent with a detailed notice rather than a brief announcement or a full report. There is no indication that this is an annual report, audit report, or any other type of filing. Therefore, the correct classification is 'DIRS' (Director's Dealing).
2025-02-25 English
Notices received under S203D and S249D of Corporations Act 2 pages 207.0KB
Board/Management Information Classification · 95% confidence The document is a formal announcement from Percheron Therapeutics Limited regarding notices received under sections 203D and 249D of the Corporations Act 2001 (Cth). These sections relate to requisitions for a general meeting and the removal and appointment of directors. The document details resolutions to remove and appoint directors and discusses the calling of a general meeting to vote on these resolutions. There is no financial data, earnings information, or report content. The document is clearly about changes in the company's board of directors and the process for shareholder voting on these changes. Therefore, it fits the category of Board/Management Information (MANG). The document length is under 5,000 characters and is not a report publication announcement but a substantive announcement about board changes. Confidence is high due to clear references to director removals and appointments under specific legal provisions.
2025-02-24 English
Update on Partnering Progress 2 pages 103.9KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement from Percheron Therapeutics Limited providing an update on a non-binding proposal to in-license a new drug development program. It discusses ongoing negotiations, potential future clinical trials, and strategic business developments. There are no financial statements, detailed financial performance data, or regulatory certifications. The document is a corporate update on capital and partnership activities rather than a full financial report or regulatory filing. It is not an earnings release, annual report, or management discussion. The content fits best under Capital/Financing Update (CAP) as it relates to a potential licensing deal and strategic partnership negotiations, which are financing-related activities. The document length is 3226 characters, which is typical for an announcement rather than a full report.
2025-02-23 English
Change of Interest of Substantial Holder from PVL 3 pages 383.8KB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Form 604' and references the Corporations Act 2001, specifically Section 671B, which pertains to notices of change of interests of substantial holders. The content details changes in voting power and relevant interests of a substantial shareholder, including dates and share quantities. This matches the description of a 'Major Shareholding Notification' which reports changes in significant share ownership levels crossing thresholds. The document is not a financial report, earnings release, or management information, but a regulatory filing about shareholding changes. Therefore, the appropriate classification is 'MRQ' for Major Shareholding Notification.
2025-02-20 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.